Patents Examined by Matthew P Coughlin
  • Patent number: 11185588
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 30, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 11186534
    Abstract: The disclosure provides chemical compounds possessing therapeutic and/or protective properties against oxidative damage. Methods of making such therapeutic and/or protective compounds and associated compositions are also provided, as are methods for their use, which include protecting cells from oxidative damage and/or inhibiting production of ROS in a cell or subject, as well as preventing or reducing the extent of tissue damage caused by an ischemic event in a subject at elevated risk of such an event.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 30, 2021
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Gary Piazza, Xi Chen, Herbert Weissbach, Shailaja Kesraju Allani
  • Patent number: 11186681
    Abstract: The invention generally relates to compositions comprising degradable polymers and methods of making degradable polymers. Specifically, the disclosed degradable polymers comprise a biodegradable polymer backbone, a nitric oxide linker moiety, and a nitric oxide molecule. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 30, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark Schoenfisch, Lei Yang, Yuan Lu
  • Patent number: 11185534
    Abstract: Prodrugs of glutamine analogs, such as prodrugs of acivicin, are disclosed.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: November 30, 2021
    Assignees: The Johns Hopkins University, Ústav organické Chemie a biochemie AV {hacek over (C)}{hacek over ( )}R, v.v.i.
    Inventors: Barbara Slusher, Pavel Majer, Lukas Tenora, Katerina Novotna, Peter Michael Hudlicky
  • Patent number: 11179402
    Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 23, 2021
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides
  • Patent number: 11179403
    Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 23, 2021
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides
  • Patent number: 11166931
    Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: November 9, 2021
    Assignee: G. POHL-BOSKAMP GMBH & CO. KG
    Inventor: Michaela Gorath
  • Patent number: 11166967
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: November 9, 2021
    Assignee: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk
  • Patent number: 11168179
    Abstract: The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: November 9, 2021
    Assignee: FACULDADE DE CIÉNCIAS DA UNIVERSIDADE DE LISBOA
    Inventors: Maria Helena Anselmo Viegas Garcia, Andreia Marques Valente, Tânia Sofia Ferreira Morais, Ana Isabel Antunes Tomaz Diniz
  • Patent number: 11161827
    Abstract: In one aspect, the disclosure relates to a mode of asymmetric induction in radical processes based on sequential combination of enantiodifferentiative H-atom abstraction and stereoretentive radical substitution. Also disclosed is an asymmetric system for stereoselective synthesis of strained 5-membered cyclic sulfamides via radical 1,5-C—H amination of sulfamoyl azides. The disclosed metalloradical system can control the degree and sense of asymmetric induction in the catalytic radical C—H amination in a systematic manner. The disclosed system is applicable to a broad scope of substrates with different types of C(sp3)—H bonds and exhibits reactivity and selectivity, providing access to both enantiomers of useful 5-membered cyclic sulfamides in a highly enantioenriched form. Also disclosed are catalysts useful in these processes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: November 2, 2021
    Assignee: The Trustees of Boston College
    Inventors: Xiao-Xiang Zhang, Kai Lang
  • Patent number: 11155683
    Abstract: A composition comprises phenolic polymer particles and a surfactant, on the phenolic polymer particles. The composition is lipophilic. A dispersion comprises the phenolic polymer particles, the surfactant, and a carrier vehicle. The carrier vehicle may be a cosmetically-acceptable fluid or a wax that is lipophilic.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: October 26, 2021
    Assignee: Nanophase Technologies Corporation
    Inventors: Harry W. Sarkas, Christopher C. Boffa, Kevin Cureton
  • Patent number: 11154552
    Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 26, 2021
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
  • Patent number: 11154516
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11155530
    Abstract: Chemoselective conjugation is achieved through redox reactivity by reacting an N-transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Chemical Tagging (ReACT) strategies for methionine-based protein functionalization. Oxaziridine (Ox) compounds serve as oxidant-mediated reagents for direct functionalization by converting methionine to the corresponding sulfimide conjugation product.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: October 26, 2021
    Assignee: The Regents of the University of California
    Inventors: Christopher J. Chang, F. Dean Toste, Alec H. Christian, Patti Zhang
  • Patent number: 11149016
    Abstract: The present invention relates to a S-substituted-2-amino-3-mercaptopropionate derivative, a preparation method and an application thereof. The S-substituted-2-amino-3-mercaptopropionate derivative in the present invention has a structure of a formula (A). The present invention also includes an application of the S-substituted-2-amino-3-mercaptopropionate derivative serving as a medicine for treating and/or preventing neurodegenerative diseases, particularly Alzheimer's disease.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 19, 2021
    Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    Inventors: Jun Zhong, Guocheng Wang
  • Patent number: 11149093
    Abstract: Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 19, 2021
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Byung Sook Moon, Ki Chung, Yunfei Chen
  • Patent number: 11149024
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 19, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Craig Robert Stewart, Simon Hardy, Andrew Stark, Alexander Hird, Qing Ye, Xiaolan Zheng, Cati Ferrar, Jan Koek, Debasis Hazra
  • Patent number: 11149034
    Abstract: 6-Thio derivatives of D-luciferin, also referred to as D-thioluciferins, having the general structure of Formula (I) are provided. Methods for synthesising D-luciferin, its derivatives, and their related 2-cyanobenzothiazole precursors are also provided. These compounds are commercially valuable due to their application in optical imaging, particularly in bioluminescence imaging.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: October 19, 2021
    Assignee: UNIVERSITY OF CAPE TOWN
    Inventors: Moegamat Anwar Jardine, Marwaan Rylands
  • Patent number: 11142513
    Abstract: The present invention belongs to the field of organic chemical synthesis, and provides a method for simultaneously preparing 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, catechol and diethyl carbonate are subjected to a transesterification reaction under the action of a catalyst to obtain 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, the combined selectivity of 2-ethoxyphenol and 1,3-benzodioxol-2-one can reach 97%. The method has the advantages of high conversion rate, high selectivity, high economic benefit, environmental friendliness and the like.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: October 12, 2021
    Inventors: Xiujing Zou, Gonglin Cheng, Xueguang Wang, Yankai Wang, Xionggang Lu, Weizhong Ding
  • Patent number: 11142539
    Abstract: Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: October 12, 2021
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Anvarhusein A. Isab, Adam Ahmed Abdullah Sulaiman, Ali Alhoshani